Patients first
Every design choice — from once-daily oral dosing to at-home convenience — starts with the person living with cancer.
About Zentia
A decade of WEE1 biology.
One clear mission.
Zentia was founded by scientists who believed the decades of research into cell-cycle control could become a new, more convenient class of cancer therapy — if the right team took it from lab bench to patient.
Milestones
The journey so far
-
2015
A company is born
Zentia launches in San Diego, spun from a conviction that WEE1 kinase — a master regulator of the cell cycle — could finally become a druggable target.
-
2018
First-in-human study
Our lead molecule enters the clinic, establishing a differentiated oral profile and the first biomarker-defined clinical strategy.
-
2021
Biomarker breakthrough
Cyclin E1 amplification emerges as a defining response signature, sharpening our patient selection and trial design.
-
2023
Registration-intent build
Late-stage development programs begin, pairing our lead asset with a companion diagnostic across global sites.
-
2026
Phase 3 ASPENOVA trial
First patient dosed in our registration-intent Phase 3 trial — a milestone on the path to bringing patients more choice.
What we believe
Values that guide every decision
Science with rigor
We hold ourselves to the highest standard of evidence, letting mechanism and data — not enthusiasm — drive decisions.
Integrity
Transparent, disciplined and honest in everything from clinical reporting to how we treat one another.
Bold collaboration
We partner across academia, patient communities and industry to move faster than any of us could alone.
Today
Where we are
A focused, late-stage company advancing one of the most studied targets in oncology.
Our progress
From one hypothesis to a global program
Today Zentia is a team of more than 200 scientists, physicians and operators working across three continents — all focused on one goal: giving patients a targeted, oral option where few non-chemotherapy choices exist.
We are proud of the discipline that got us here: rigorous translational science, a companion diagnostic designed alongside the drug, and trials designed to answer questions patients actually need answered.
- 200+ employees across US and EU
- 40+ active clinical trial sites
- Led by a team with 30+ years of oncology development experience